Showing 2644 results
- Media Release /Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
- Media Release /Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
- Media Release /If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
- Media Release /Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
- Media Release /SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
- Media Release /
Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels
SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce… - Media Release /"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
- Media Release /Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
- Media Release /Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
- Media Release /Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
Pagination
- ‹ Previous page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- …
- 265
- › Next page